Stockpolly
Search
Delisting risk
SXTP · NASDAQ · Biotechnology

60 Degrees Pharmaceuticals (SXTP)

Develops and markets tafenoquine medicines for malaria prevention and vector-borne diseases.

$0.9600
Pre-market−0.01 (−1.02%)
At close$0.9699(−4.91%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000001000
Gross profit000000000000
221422222222
Research & development000311001101
121112222122
General & administrative121112222122
Other expenses000000000000
Operating income−2−2−1−4−2−2−2−2−2−2−2−2
602000000000
Interest expense000000000000
Other non-operating income−60−2000000000
Income before tax4−20−4−2−2−2−2−2−1−2−2
Income tax expense000000000000
Net income from continuing operations4−20−4−2−2−2−2−2−1−2−2
Other adjustments000000000000
Net income4−20−4−2−2−2−2−2−1−2−2
EPS, basic$2.88−$1.36$7.32−$16.92−$3.52−$18.00−$6.24−$5.00−$2.52−$1.35−$1.28−$0.90
EPS, diluted$2.88−$1.36$7.32−$16.44−$3.52−$18.00−$6.24−$5.00−$2.52−$1.35−$1.28−$0.90
Weighted average shares, basic100000001123
Weighted average shares, diluted100000001123
EBITDA4−20−4−2−2−2−2−2−1−2−2
Depreciation & amortization000000000000
EBIT4−20−4−2−2−2−2−2−1−2−2